Announcements Trials
Browse Landscape

Phase

Phase 2 134Phase 1 19Phase 3 16Phase 1/2 11Phase NA 3Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Fulvestrant × Clear all
NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

University of Pittsburgh

Phase EARLY_PHASE1 Completed
7 enrolled 13 charts
Breast

Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡